Plant-made immunotoxin building blocks: A roadmap for producing therapeutic antibody-toxin fusions

Akinrinmade, 2017, Human MAP Tau Based Targeted Cytolytic Fusion Proteins, Biomedicines, 5, 36, 10.3390/biomedicines5030036 Alewine, 2015, Advances in anticancer immunotoxin therapy, Oncologist, 20, 176, 10.1634/theoncologist.2014-0358 Allahyari, 2017, Immunotoxin: A new tool for cancer therapy, Tumour Biol., 39, 10.1177/1010428317692226 Amani, 2020, ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies, Curr. Drug Del., 17, 23, 10.2174/1567201816666191121145109 Amet, 2009, Insertion of the designed helical linker led to increased expression of tf-based fusion proteins, Pharm. Res., 26, 523, 10.1007/s11095-008-9767-0 Amico, 2003, Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3, Blood, 101, 4589, 10.1182/blood-2002-07-2311 Antignani, 2013, Immunotoxins: the role of the toxin, Toxins (Basel), 5, 1486, 10.3390/toxins5081486 Arai, 2001, Design of the linkers which effectively separate domains of a bifunctional fusion protein, Protein Eng. Des. Sel, 14, 529, 10.1093/protein/14.8.529 Argos, 1990, An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion, J. Mol. Biol., 211, 943, 10.1016/0022-2836(90)90085-Z Audi, 2005, Ricin poisoning: a comprehensive review, JAMA, 294, 2342, 10.1001/jama.294.18.2342 Azadpour, 2018, Evaluating cytotoxic effects of recombinant fragaceatoxin C pore forming toxin against AML cell lines, Iran J Basic Med Sci, 21, 878 Babashov, 2017, Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma, Curr. Oncol., 24, e6, 10.3747/co.24.3369 Badr, 2014, Methotrexate-gelonin conjugate - an inhibitor of MCF-7 cells expressing the dihydrofolate receptor, Biol. Chem., 395, 1461, 10.1515/hsz-2013-0270 Bae, 2014, Do value thresholds for oncology drugs differ from nononcology drugs?, J Manag Care Spec Pharm, 20, 1086 Bai, 2006, Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization, Pharm. Res., 23, 2116, 10.1007/s11095-006-9059-5 Baluna, 1997, Vascular leak syndrome: a side effect of immunotherapy, Immunopharmacology, 37, 117, 10.1016/S0162-3109(97)00041-6 Baneyx, 2004, Recombinant protein folding and misfolding in Escherichia coli, Nat. Biotechnol., 22, 1399, 10.1038/nbt1029 Barenholz, 2012, Doxil(R)--the first FDA-approved nano-drug: lessons learned, J. Controlled Release, 160, 117, 10.1016/j.jconrel.2012.03.020 Becher, 2006, Genetically engineered models have advantages over xenografts for preclinical studies, Cancer Res., 66, 3355, 10.1158/0008-5472.CAN-05-3827 Beck, 2017, Strategies and challenges for the next generation of antibody-drug conjugates, Nat. Rev. Drug Discov., 16, 315, 10.1038/nrd.2016.268 Bergamaschi, 1996, Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis, Br. J. Haematol., 93, 789, 10.1046/j.1365-2141.1996.d01-1730.x Bhakta, 2013, Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers, Methods Mol. Biol., 1045, 189, 10.1007/978-1-62703-541-5_11 Birrer, 2019, Antibody-Drug Conjugate-Based Therapeutics: State of the Science, J. Natl. Cancer Inst., 10.1093/jnci/djz035 Bolognesi, 1990, Purification and properties of new ribosome-inactivating proteins with RNA N-glycosidase activity, Biochim. Biophys. Acta, 1087, 293, 10.1016/0167-4781(90)90002-J Borthakur, 2013, Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies, Haematologica, 98, 217, 10.3324/haematol.2012.071092 Bortolotti, 2018, Bouganin, an Attractive Weapon for Immunotoxins, Toxins (Basel), 10, 10.3390/toxins10080323 Boswell, 2011, Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats, Bioconj. Chem., 22, 1994, 10.1021/bc200212a Braun, 2016, Urokinase-controlled tumor penetrating peptide, J. Controlled Release, 232, 188, 10.1016/j.jconrel.2016.04.027 Brinkmann, 1993, A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin, Proc. Natl. Acad. Sci. U. S. A., 90, 547, 10.1073/pnas.90.2.547 Brodzik, 2006, Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells, Proc. Natl. Acad. Sci. U. S. A., 103, 8804, 10.1073/pnas.0603043103 Buhler, 2010, Influence of structural variations on biological activity of anti-PSMA scFv and immunotoxins targeting prostate cancer, Anticancer Res., 30, 3373 Buntru, 2015, A versatile coupled cell-free transcription-translation system based on tobacco BY-2 cell lysates, Biotechnol. Bioeng., 112, 867, 10.1002/bit.25502 Buyel, 2018, Plants as sources of natural and recombinant anti-cancer agents, Biotechnol. Adv., 36, 506, 10.1016/j.biotechadv.2018.02.002 Buyel, 2019, Plant Molecular Farming - Integration and Exploitation of Side Streams to Achieve Sustainable Biomanufacturing, Front Plant Sci, 9, 1893, 10.3389/fpls.2018.01893 Buyel, 2014, Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study, J Vis Exp, 51216 Buyel, 2017, Very-large-scale production of antibodies in plants: The biologization of manufacturing, Biotechnol. Adv., 35, 458, 10.1016/j.biotechadv.2017.03.011 Buyel, 2013, Predictive models for the accumulation of a fluorescent marker protein in tobacco leaves according to the promoter/5’UTR combination, Biotchnology and Bioengeneering, 110, 471, 10.1002/bit.24715 Buyel, 2016, Comparison of Tobacco Host Cell Protein Removal Methods by Blanching Intact Plants or by Heat Treatment of Extracts, J Vis Exp, 10.3791/54343 Cao, 2009, Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies, Cancer Res., 69, 8987, 10.1158/0008-5472.CAN-09-2693 Cao, 2014, Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies, Oncogene, 33, 429, 10.1038/onc.2012.612 Capell, 2020, Potential Applications of Plant Biotechnology against SARS-CoV-2, Trends Plant Sci., 25, 635, 10.1016/j.tplants.2020.04.009 Carbone, 2018, Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study, J. Clin. Oncol., 36, 8507, 10.1200/JCO.2018.36.15_suppl.8507 Carreras-Sangra, 2008, The therapeutic potential of fungal ribotoxins, Curr. Pharm. Biotechnol., 9, 153, 10.2174/138920108784567335 Chaudhary, 1989, A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin, Nature, 339, 394, 10.1038/339394a0 Chen, 2010, Design of an in vivo cleavable disulfide linker in recombinant fusion proteins, BioTechniques, 49, 513, 10.2144/000113450 Chen, 2013, Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin, Onco Targets Ther., 7, 45 Chen, 2013, Fusion protein linkers: Property, design and functionality, Adv. Drug Del. Rev., 65, 1357, 10.1016/j.addr.2012.09.039 Chen, 2017, Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy, Molecules, 22, 1281, 10.3390/molecules22081281 Choudhary, 2011, Therapeutic potential of anticancer immunotoxins, Drug Discov. Today, 16, 495, 10.1016/j.drudis.2011.04.003 Chuan Xia, 2003, Purification and characterization of Moschatin, a novel type I ribosome-inactivating protein from the mature seeds of pumpkin (Cucurbita moschata), and preparation of its immunotoxin against human melanoma cells, Cell Res., 13, 369, 10.1038/sj.cr.7290182 Citores, 2002, Targeting cancer cells with transferrin conjugates containing the non-toxic type 2 ribosome-inactivating proteins nigrin b or ebulin l, Cancer Lett., 184, 29, 10.1016/S0304-3835(02)00169-6 Coats, 2019, Antibody Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index, Clin. Cancer. Res., 10.1158/1078-0432.CCR-19-0272 Collier, 1979, Structure-activity relationships in diphtheria toxin and exotoxin A from Pseudomonas aeruginosa, Prog. Clin. Biol. Res., 31, 751 Cong, 2016, Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations, Protein Sci., 25, 1451, 10.1002/pro.2941 Cox, 2006, Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor, Nat. Biotechnol., 24, 1591, 10.1038/nbt1260 Cui, 2012, Recombinant hHscFv-RC-RNase protein derived from transgenic tobacco acts as a bifunctional molecular complex against hepatocellular carcinoma, Biotechnol. Appl. Biochem., 59, 323, 10.1002/bab.1039 Dai, 2017, A structural and mechanistic study of π-clamp-mediated cysteine perfluoroarylation, Sci. Rep., 7, 7954, 10.1038/s41598-017-08402-2 De Groot, 2008, Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates, Curr. Opin. Pharm., 8, 620, 10.1016/j.coph.2008.08.002 Deonarain, 2018, Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?, Antibodies, 7, 16, 10.3390/antib7020016 Devlin, 2017, QALYs as a measure of value in cancer, J Cancer Policy, 11, 19, 10.1016/j.jcpo.2016.09.005 Dhillon, 2018, Moxetumomab Pasudotox: First Global Approval, Drugs, 78, 1763, 10.1007/s40265-018-1000-9 Dosio, 1996, Synthesis of different immunotoxins composed by ribosome inactivating proteins non-covalently bound to monoclonal antibody, Farmaco, 51, 477 Du, 2008, Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity, Cancer Res., 68, 6300, 10.1158/0008-5472.CAN-08-0461 Du, 2008, FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins, Blood, 111, 338, 10.1182/blood-2007-07-102350 Eck, 1999, Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain, Eur. J. Biochem., 264, 775, 10.1046/j.1432-1327.1999.00638.x Ecker, 2015, The therapeutic monoclonal antibody market, MAbs, 7, 9, 10.4161/19420862.2015.989042 Edgue, 2017, Antibodies from plants for bionanomaterials, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 9, e1462, 10.1002/wnan.1462 Endo, 1988, The RNA N-glycosidase activity of ricin A-chain. The characteristics of the enzymatic activity of ricin A-chain with ribosomes and with rRNA, J. Biol. Chem., 263, 8735, 10.1016/S0021-9258(18)68367-X Entwistle, 2013, The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors Escajadillo, 2018, Pharmacological Targeting of Pore-Forming Toxins as Adjunctive Therapy for Invasive Bacterial Infection, Toxins (Basel), 10, 542, 10.3390/toxins10120542 Evans, 1986, Sequence-imposed structural constraints in the TonB protein of E. coli, FEBS Lett., 208, 211, 10.1016/0014-5793(86)81020-1 Fanale, 2018, Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study, J. Clin. Oncol., 36, 7580, 10.1200/JCO.2018.36.15_suppl.7580 Faye, 2005, Protein modifications in the plant secretory pathway: current status and practical implications in molecular pharming, Vaccine, 23, 1770, 10.1016/j.vaccine.2004.11.003 Ferreras, 2011, Use of Ribosome-Inactivating Proteins from Sambucus for the Construction of Immunotoxins and Conjugates for Cancer Therapy, Toxins (Basel), 3, 420, 10.3390/toxins3050420 Fischer, 2020, Molecular farming - The slope of enlightenment, Biotechnol. Adv., 10.1016/j.biotechadv.2020.107519 Fischer, 2000, Antibody production by molecular farming in plants, J. Biol. Regul. Homeost. Agents, 14, 83 Fischer, 2012, GMP issues for recombinant plant-derived pharmaceutical proteins, Biotechnol. Adv., 30, 434, 10.1016/j.biotechadv.2011.08.007 Flavell, 1995, Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours, Br. J. Cancer, 72, 1373, 10.1038/bjc.1995.517 Francisco, 1997, Expression and Characterization of Bryodin 1 and a Bryodin 1-Based Single-Chain Immunotoxin from Tobacco Cell Culture, Bioconj. Chem., 8, 708, 10.1021/bc970107k Francisco, 1997, Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1, J. Biol. Chem, 272, 24165, 10.1074/jbc.272.39.24165 Frankel, 2008, Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia, Leuk. Lymphoma, 49, 543, 10.1080/10428190701799035 Frankel, 2015, Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma, Haematologica, 100, 794, 10.3324/haematol.2015.123711 Friedman, 1993, BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells, Cancer Res., 53, 334 Frigerio, 1998, Free ricin A chain, proricin, and native toxin have different cellular fates when expressed in tobacco protoplasts, J. Biol. Chem., 273, 14194, 10.1074/jbc.273.23.14194 Gadadhar, 2013, Abrin immunotoxin: targeted cytotoxicity and intracellular trafficking pathway, PLoS One, 8, e58304, 10.1371/journal.pone.0058304 Garner, 2019, Predicting future cancer incidence by age and gender, J. Clin. Oncol., 37, 1559, 10.1200/JCO.2019.37.15_suppl.1559 Gengenbach, 2019, Comparison of microbial and transient expression (tobacco plants and plant-cell packs) for the production and purification of the anti-cancer mistletoe lectin viscumin, Biotechnol. Bioeng., 116, 2236, 10.1002/bit.27076 Gengenbach, 2020, Robot Cookies – Plant Cell Packs as an Automated High-Throughput Screening Platform Based on Transient Expression, Front Bioeng Biotechnol, 8, 10.3389/fbioe.2020.00393 George, 2002, An analysis of protein domain linkers: their classification and role in protein folding, Protein Eng., 15, 871, 10.1093/protein/15.11.871 Ghafoor, 2018, Targeting mesothelin in ovarian cancer, Oncotarget, 9, 36050, 10.18632/oncotarget.26350 Giansanti, 2018, Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins, Toxins (Basel), 10, 10.3390/toxins10020082 Gilabert-Oriol, 2014, Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy, Curr. Pharm. Des., 20, 6584, 10.2174/1381612820666140826153913 Gilabert-Oriol, 2017, Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma, Caner Immunol Immun, 66, 1217, 10.1007/s00262-017-2013-z Gleba, 2005, Magnifection--a new platform for expressing recombinant vaccines in plants, Vaccine, 23, 2042, 10.1016/j.vaccine.2005.01.006 Goldberg, 1995, Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer, Clin. Cancer Res., 1, 57 Golombek, 2018, Tumor targeting via EPR: Strategies to enhance patient responses, Adv. Drug Del. Rev., 130, 17, 10.1016/j.addr.2018.07.007 Goyal, A. & Batra, J. K., 2000. Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. Biocehm. J., 345 Pt 2, 247-54. Grabsztunowicz, 2017, Post-translational Modifications in Regulation of Chloroplast Function: Recent Advances, Front Plant Sci, 8, 240, 10.3389/fpls.2017.00240 Günhan, 2008, Expression and purification of cysteine introduced recombinant saporin, Protein Expression Purif., 58, 203, 10.1016/j.pep.2007.11.005 Gurkan, 2005, Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris, Microb. Cell Fact., 4, 33, 10.1186/1475-2859-4-33 Hakim, 2009, Inclonals, mAbs, 1, 281, 10.4161/mabs.1.3.8492 Hartwell, 2011, Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation. Appendix 8, Net benefit framework, NIHR Journals Library, 297, 1 Hauner, 2017, Side effects of chemotherapy, Urologe, 56, 472, 10.1007/s00120-017-0338-z Hehle, 2016, Site-targeted mutagenesis for stabilization of recombinant monoclonal antibody expressed in tobacco (Nicotiana tabacum) plants, FASEB J., 30, 1590, 10.1096/fj.15-283226 Hernandez, 2018, Pricing of monoclonal antibody therapies: higher if used for cancer?, Am J Manag Care, 24, 109 Hicks, 2019, The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models, Haematologica, 104, 1633, 10.3324/haematol.2018.211011 Hoffmann, 2017, Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs), Oncoimmunology, 7, e1395127, 10.1080/2162402X.2017.1395127 Hristodorov, 2013, Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo, Br. J. Cancer, 109, 1570, 10.1038/bjc.2013.457 Huntington, S. F., Von Keudell, G., Davidoff, A. J., Gross, C. P. & Prasad, S. A., 2018. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. J. Clin. Oncol., Jco1800122. https://doi.org/10.1200/jco.18.00122. Jahanian-Najafabadi, 2012, Assessment of selective toxicity of insect cell expressed recombinant A1-GMCSF protein toward GMCSF receptor bearing tumor cells, Res. Pharm. Sci., 7, 133 Jansing, 2019, CRISPR/Cas9-mediated knockout of six glycosyltransferase genes in Nicotiana benthamiana for the production of recombinant proteins lacking β-1,2-xylose and core α-1,3-fucose, Plant Biotechnol. J., 17, 350, 10.1111/pbi.12981 Jeong, 2019, Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis, J. Clin. Med., 8, 143, 10.3390/jcm8020143 Ji, 2019, The histone methyltransferase Setd2 is indispensable for V(D)J recombination, Nat. Commun., 10, 3353, 10.1038/s41467-019-11282-x Jiménez, 2015, Ebulin from dwarf elder (Sambucus ebulus L.): a mini-review, Toxins (Basel), 7, 648, 10.3390/toxins7030648 Johnson, 1989, A point mutation of proline 308 in diphtheria toxin B chain inhibits membrane translocation of toxin conjugates, J. Biol. Chem., 264, 17739, 10.1016/S0021-9258(19)84633-1 Johnson, 1993, The role of proline 345 in diphtheria toxin translocation, J. Biol. Chem., 268, 3514, 10.1016/S0021-9258(18)53724-8 Jones, 2016, A deimmunised form of the ribotoxin, alpha-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead, Protein Eng. Des. Sel., 10.1093/protein/gzw045 Jungbauer, 2007, Current status of technical protein refolding, J. Biotechnol., 128, 587, 10.1016/j.jbiotec.2006.12.004 Kamath, 2015, Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates, Pharm. Res., 32, 3470, 10.1007/s11095-014-1584-z Kaplan, 2016, Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A, Toxins (Basel), 8, 217, 10.3390/toxins8080217 Kaplan, 2018, Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering, Mol. Cancer Ther., 17, 1486, 10.1158/1535-7163.MCT-17-1041 Kaufman, 2017, The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31(st) anniversary annual meeting, J. Immunother. Cancer, 5, 38, 10.1186/s40425-017-0241-6 Kelley, 2009, Industrialization of mAb production technology: the bioprocessing industry at a crossroads, MAbs, 1, 443, 10.4161/mabs.1.5.9448 Kim, 2014, Statistical Modeling of the Drug Load Distribution on Trastuzumab Emtansine (Kadcyla), a Lysine-Linked Antibody Drug Conjugate, Bioconj. Chem., 25, 1223, 10.1021/bc5000109 Kim, 2020, Critical Issues in the Development of Immunotoxins for Anticancer Therapy, J. Pharm. Sci., 109, 104, 10.1016/j.xphs.2019.10.037 Klutz, 2016, Cost evaluation of antibody production processes in different operation modes, Chem. Eng. Sci., 141, 63, 10.1016/j.ces.2015.10.029 Knödler, 2019, Seasonal Weather Changes Affect the Yield and Quality of Recombinant Proteins Produced in Transgenic Tobacco Plants in a Greenhouse Setting, Front Plant Sci, 10, 10.3389/fpls.2019.01245 Knödler, 2019, Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study, J Vis Exp, 10.3791/59933 Komarova, 2011, Plant-made trastuzumab (herceptin) inhibits HER2/Neu+ cell proliferation and retards tumor growth, PLoS One, 6, e17541, 10.1371/journal.pone.0017541 Kowalski, 2012, A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin, J. Urol., 188, 1712, 10.1016/j.juro.2012.07.020 Kreitman, 1998, Immunotoxins for targeted cancer therapy, Adv. Drug Del. Rev., 31, 53, 10.1016/S0169-409X(97)00094-X Lambert, 2017, Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review, Adv. Ther., 34, 1015, 10.1007/s12325-017-0519-6 Lansigan, 2010, Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma, Cancer Manag. Res., 2, 53, 10.2147/CMAR.S5009 Li, 2010, Purification of EGF-TCS recombinant fusion protein and its targeting action on human tumor cells, in vitro., 1316 Li, 2017, Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials, Nanotheranostics, 1, 346, 10.7150/ntno.19380 Liu, 2000, Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin, Cancer Res., 60, 6061 Liu, 2000, Expression of an Anti-CD3 Single-Chain Immunotoxin with a Truncated Diphtheria Toxin in a Mutant CHO Cell Line, Protein Expression Purif., 19, 304, 10.1006/prep.2000.1255 Liu, 2012, Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity, mAbs, 4, 57, 10.4161/mabs.4.1.18348 Liu, 2017, A novel tumor-activated ALA fusion protein for specific inhibition on the growth and invasion of breast cancer cells MDA-MB-231, Drug Deliv., 24, 1811, 10.1080/10717544.2017.1406560 Lorusso, 1995, Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer, Am. J. Clin. Oncol., 18, 307, 10.1097/00000421-199508000-00008 Lozano, 2012, Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2095, 10.1016/S0140-6736(12)61728-0 Lynch, 1997, Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin, J. Clin. Oncol., 15, 723, 10.1200/JCO.1997.15.2.723 Ma, 2015, Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants, Plant Biotechnol. J., 13, 1106, 10.1111/pbi.12416 Manoukian, 2009, Denileukin diftitox: a novel immunotoxin, Expert Opin. Biol. Ther., 9, 1445, 10.1517/14712590903348135 Marseille, 2015, Thresholds for the cost-effectiveness of interventions: alternative approaches, Bull. W.H.O., 93, 118, 10.2471/BLT.14.138206 Mccombs, 2015, Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry, AAPS J, 17, 339, 10.1208/s12248-014-9710-8 Mccormick, 2001, Immunization with an Interferon-γ–gp120 Fusion Protein Induces Enhanced Immune Responses to Human Immunodeficiency Virus gp120, J. Infect. Dis., 184, 1423, 10.1086/324371 Mcelroy, 2018, Taxol® Biosynthesis and Production: From Forests to Fermenters Menzel, 2016, Optimized Blanching Reduces the Host Cell Protein Content and Substantially Enhances the Recovery and Stability of Two Plant-Derived Malaria Vaccine Candidates, Front Plant Sci, 7, 1, 10.3389/fpls.2016.00159 Messing, 1992, Epidermal growth factor and its receptor: markers of -and targets for- chemoprevention of bladder cancer, J. Cell. Biochem., 16i, 56, 10.1002/jcb.240501312 Miao, 2016, The Binding Site Barrier Elicited by Tumor-Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors, ACS nano, 10, 9243, 10.1021/acsnano.6b02776 Mirzaee, 2018, Expression of VGRNb-PE immunotoxin in transplastomic lettuce (Lactuca sativa L.), Plant Mol. Biol., 97, 103, 10.1007/s11103-018-0726-9 Mladenov, 2015, The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia, Int. J. Cancer, 137, 2729, 10.1002/ijc.29628 Mladenov, 2016, CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo, Oncotarget, 7, 67166, 10.18632/oncotarget.11568 Moehring, 1983, Strains of CHO-K1 cells resistant to Pseudomonas exotoxin A and cross-resistant to diphtheria toxin and viruses, Infect. Immun., 41, 998, 10.1128/IAI.41.3.998-1009.1983 Mohammed, 2012, The Pseudomonas aeruginosa exotoxin A translocation domain facilitates the routing of CPP-protein cargos to the cytosol of eukaryotic cells, J. Controlled Release, 164, 58, 10.1016/j.jconrel.2012.10.006 Montemurro, 2019, Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1, Eur. J. Cancer, 109, 92, 10.1016/j.ejca.2018.12.022 Moore, 2018, FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer, Future Oncol., 14, 1669, 10.2217/fon-2017-0646 Moshiri, 2016, Ricin Toxicity: Clinical and Molecular Aspects, Rep. Biochem. Mol. Biol., 4, 60 Moss, 2019, Deimmunizing substitutions in Pseudomonas exotoxin domain III perturb antigen processing without eliminating T-cell epitopes, J. Biol. Chem., 294, 4667, 10.1074/jbc.RA118.006704 Mungra, 2019, Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells, Oncotarget, 10, 897, 10.18632/oncotarget.26618 Mutter, 2018, Modular Pore-Forming Immunotoxins with Caged Cytotoxicity Tailored by Directed Evolution, ACS Chem. Biol., 13, 3153, 10.1021/acschembio.8b00720 Myers, 1991, Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials, J. Immunol. Methods, 136, 221, 10.1016/0022-1759(91)90009-5 Nagamune, 2017, Biomolecular engineering for nanobio/bionanotechnology, Nano Convergence, 4, 9, 10.1186/s40580-017-0103-4 Nandi, 2016, Techno-economic analysis of a transient plant-based platform for monoclonal antibody production, mAbs, 8, 1456, 10.1080/19420862.2016.1227901 Nessler, 2020, Increased Tumor Penetration of Single-Domain Antibody Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models, Cancer Res., 10.1158/0008-5472.CAN-19-2295 Olombrada, 2017, Fungal Ribotoxins: A Review of Potential Biotechnological Applications, Toxins (Basel), 9, 10.3390/toxins9020071 Olsnes, 1978, Purification and characterization of the highly toxic lectin modeccin, J. Biol. Chem., 253, 5069, 10.1016/S0021-9258(17)34658-6 Ott, 2019, A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma, Cancer, 125, 1113, 10.1002/cncr.31892 Ou, 2018, Bioprocess development of antibody-drug conjugate production for cancer treatment, PLoS One, 13, 10.1371/journal.pone.0206246 Pai, 1991, Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer, J. Clin. Oncol, 9, 2095, 10.1200/JCO.1991.9.12.2095 Palanca-Wessels, 2014, Advances in the treatment of hematologic malignancies using immunoconjugates, Blood, 123, 2293, 10.1182/blood-2013-10-492223 Pasqualucci, 1995, Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma, Blood, 85, 2139, 10.1182/blood.V85.8.2139.bloodjournal8582139 Paul, 2011, Plant-made pharmaceuticals: Leading products and production platforms, Biotechnol. Appl. Biochem., 58, 58, 10.1002/bab.6 Perez, 2014, Antibody-drug conjugates: current status and future directions, Drug Discov. Today, 19, 869, 10.1016/j.drudis.2013.11.004 Peters, 2015, Antibody-drug conjugates as novel anti-cancer chemotherapeutics, Biosci. Rep., 35, 10.1042/BSR20150089 Peyret, 2013, The pEAQ vector series: the easy and quick way to produce recombinant proteins in plants, Plant Mol. Biol., 83, 51, 10.1007/s11103-013-0036-1 Peyret, 2019, Improving plant transient expression through the rational design of synthetic 5’ and 3’ untranslated regions, Plant methods, 15, 108, 10.1186/s13007-019-0494-9 Pickard, 2012, Comparison of FACT- and EQ-5D-based utility scores in cancer, Value Health, 15, 305, 10.1016/j.jval.2011.11.029 Pilbrough, 2009, Intraclonal protein expression heterogeneity in recombinant CHO cells, PLoS One, 4, e8432, 10.1371/journal.pone.0008432 Pirie, 2011, Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties, J. Biol. Chem., 286, 4165, 10.1074/jbc.M110.186973 Powell, 2007, Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo, J. Immunol., 179, 4919, 10.4049/jimmunol.179.7.4919 Purcell, 2017, Production of Functional Anti-Ebola Antibodies in Pichia pastoris, ACS Synth Biol, 6, 2183, 10.1021/acssynbio.7b00234 Rademacher, 2009, Production and localization of recombinant pharmaceuticals in transgenic seeds, Methods Mol. Biol., 483, 69, 10.1007/978-1-59745-407-0_5 Rademacher, 2019, Plant cell packs: a scalable platform for recombinant protein production and metabolic engineering, Plant Biotechnol. J., 1 Ratts, 2003, The cytosolic entry of diphtheria toxin catalytic domain requires a host cell cytosolic translocation factor complex, J. Cell Biol., 160, 1139, 10.1083/jcb.200210028 Ricart, 2011, Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin, Clin. Cancer. Res., 17, 6417, 10.1158/1078-0432.CCR-11-0486 Robinson, 2015, Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria, Nat. Commun., 6, 8072, 10.1038/ncomms9072 Rosales-Mendoza, 2015, Carrot Cells: A Pioneering Platform for Biopharmaceuticals Production, Mol. Biotechnol., 57, 219, 10.1007/s12033-014-9837-y Roses, 2009, HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer, Cancer Epidemiol. Biomarkers Prev., 18, 1386, 10.1158/1055-9965.EPI-08-1101 Rühl, 2018, A linear epitope coupled to DsRed provides an affinity ligand for the capture of monoclonal antibodies, J. Chromatogr., 1571, 55, 10.1016/j.chroma.2018.08.014 Ruiz-De-La-Herrán, 2019, Inclusion of a Furin Cleavage Site Enhances Antitumor Efficacy against Colorectal Cancer Cells of Ribotoxin α-Sarcin- or RNase T1-Based Immunotoxins, Toxins (Basel), 11, 10.3390/toxins11100593 Rup, 2017, Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems-The taliglucerase alfa story, PLoS One, 12, e0186211, 10.1371/journal.pone.0186211 Sabourin, 2007, A flexible protein linker improves the function of epitope-tagged proteins in Saccharomyces cerevisiae, Yeast, 24, 39, 10.1002/yea.1431 Sack, 2015, From Gene to Harvest: insights into upstream process development for the GMP production of a monoclonal antibody in transgenic tobacco plants, Plant Biotechnol. J., 13, 10.1111/pbi.12438 Salehinia, 2018, Improvement of solubility and refolding of an anti-human epidermal growth factor receptor 2 single-chain antibody fragment inclusion bodies, Res. Pharm. Sci., 13, 566, 10.4103/1735-5362.245968 Sapra, 2005, Preclinical Safety and Efficacy of Two Novel Immunotoxins Consisting of Ranpirnase (Rap) Fused to an Internalizing Anti-CD74 Humanized IgG4 Antibody in Human Non-Hodgkin’s Lymphoma Xenografts, Blood, 106, 346, 10.1182/blood.V106.11.346.346 Schillberg, 2019, Critical Analysis of the Commercial Potential of Plants for the Production of Recombinant Proteins, Front Plant Sci, 10, 10.3389/fpls.2019.00720 Sehnke, 1994, Expression of active, processed ricin in transgenic tobacco, J. Biol. Chem., 269, 22473, 10.1016/S0021-9258(17)31668-X Selby, 2019, Gemtuzumab Ozogamicin: Back Again, J Adv Pract Oncol, 10, 68 Selim, 2016, Immunological characterization of diphtheria toxin recovered from Corynebacterium pseudotuberculosis, Saudi J. Biol. Sci., 23, 282, 10.1016/j.sjbs.2015.11.004 Shan, 2013, Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies, J Basic Clin Med, 2, 1 Shao, 2012, Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study, Cancer, 118, 2986, 10.1002/cncr.26596 Shapira, 2010, Toxin-based therapeutic approaches, Toxins (Basel), 2, 2519, 10.3390/toxins2112519 Shiroiwa, 2011, Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial, Br. J. Cancer, 105, 1273, 10.1038/bjc.2011.390 Siegel, 2019, Cancer statistics, 2019, CA: A Cancer Jornal for Clinicians, 69, 7 Siegel, 2020, Cancer statistics, 2020, CA Cancer J. Clin., 70, 7, 10.3322/caac.21590 Simon, 2016, Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers, Toxins (Basel), 8, 137, 10.3390/toxins8050137 Singh, 2015, Protein recovery from inclusion bodies of Escherichia coli using mild solubilization process, Microb. Cell Fact., 14, 41, 10.1186/s12934-015-0222-8 Singh, 2020, Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation, AAPS J, 22, 28, 10.1208/s12248-019-0387-x Sochaj, 2015, Current methods for the synthesis of homogeneous antibody–drug conjugates, Biotechnol. Adv., 33, 775, 10.1016/j.biotechadv.2015.05.001 Spiegel, 2018 Stahnke, 2008, Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes, Mol. Cancer Ther., 7, 2924, 10.1158/1535-7163.MCT-08-0554 Staudinger, 2014, The novel immunotoxin HM1.24-ETA′ induces apoptosis in multiple myeloma cells, Blood Cancer J, 4, e219, 10.1038/bcj.2014.38 Stocker, 2003, Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells, Protein Expression Purif., 28, 211, 10.1016/S1046-5928(02)00709-X Stone, 1996, A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma, Blood, 88, 1188, 10.1182/blood.V88.4.1188.bloodjournal8841188 Strasser, 2013, Engineering of human-type O-glycosylation in Nicotiana benthamiana plants, Bioengineered, 4, 191, 10.4161/bioe.22857 Strebhardt, 2008, Paul Ehrlichs magic bullet concept: 100 years of progress, Nat. Rev. Cancer, 8, 473, 10.1038/nrc2394 Sun, 2017, Enhancing Tumor Penetration of Nanomedicines, Biomacromolecules, 18, 1449, 10.1021/acs.biomac.7b00068 Takamatsu, 1990, Production of enkephalin in tobacco protoplasts using tobacco mosaic virus RNA vector, FEBS Lett., 269, 73, 10.1016/0014-5793(90)81121-4 Tamargo, 2015, Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide, Eur. J. Clin. Pharmacol., 71, 549, 10.1007/s00228-015-1832-0 Tang, 2014, Investigating the optimal size of anticancer nanomedicine, Proc. Natl. Acad. Sci. U. S. A., 111, 15344, 10.1073/pnas.1411499111 Tang, 2016, Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells, Oncotarget, 7, 34070, 10.18632/oncotarget.8710 Tekoah, 2013, Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems, Biosci. Rep., 33, 10.1042/BSR20130081 Thomas, 2002, Furin at the cutting edge: From protein traffic to embryogenesis and disease, Nat. Rev. Mol. Cell Biol., 3, 753, 10.1038/nrm934 Tolcher, 2016, Antibody drug conjugates: lessons from 20 years of clinical experience, Ann. Oncol., 27, 2168, 10.1093/annonc/mdw424 Tomé-Amat, 2015, Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts, SpringerPlus, 4, 168, 10.1186/s40064-015-0943-5 Tonevitsky, 1996, Immunotoxins containing A-chain of mistletoe lectin I are more active than immunotoxins with ricin A-chain, FEBS Lett., 392, 166, 10.1016/0014-5793(96)00803-4 Tran, 2013, Production of unique immunotoxin cancer therapeutics in algal chloroplasts, Proc. Natl. Acad. Sci. U. S. A., 110, E15, 10.1073/pnas.1214638110 Tsuchikama, 2018, Antibody-drug conjugates: recent advances in conjugation and linker chemistries, Protein Cell, 9, 33, 10.1007/s13238-016-0323-0 Tur, 2003, Recombinant CD64-Specific Single Chain Immunotoxin Exhibits Specific Cytotoxicity against Acute Myeloid Leukemia Cells, Cancer Res., 63, 8414 Tur, 2011, In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA′ in a human acute myeloid leukemia xenograft tumor model, Int. J. Cancer, 129, 1277, 10.1002/ijc.25766 Tusé, 2015, Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma, BioMed Res. Int., 2015, 648143, 10.1155/2015/648143 Tusé, 2020, The Emergency Response Capacity of Plant-Based Biopharmaceutical Manufacturing-What It Is and What It Could Be, Front Plant Sci, 11, 10.3389/fpls.2020.594019 Van Rosmalen, 2017, Tuning the Flexibility of Glycine-Serine Linkers To Allow Rational Design of Multidomain Proteins, Biochemistry, 56, 6565, 10.1021/acs.biochem.7b00902 Vandooren, 2016, Proteases in cancer drug delivery, Adv. Drug Del. Rev., 97, 144, 10.1016/j.addr.2015.12.020 Verch, 1998, Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector, J. Immunol. Methods, 220, 69, 10.1016/S0022-1759(98)00149-5 Vitetta, 1991, Phase I immunotoxin trial in patients with B-cell lymphoma, Cancer Res., 51, 4052 Volynsky, 2019, Specific refolding pathway of viscumin A chain in membrane-like medium reveals a possible mechanism of toxin entry into cell, Sci. Rep., 9, 413, 10.1038/s41598-018-36310-6 Walpole, 2012, The weight of nations: an estimation of adult human biomass, BMC Public Health, 12, 439, 10.1186/1471-2458-12-439 Walsh, 2013, Ribosome-inactivating proteins: potent poisons and molecular tools, Virulence, 4, 774, 10.4161/viru.26399 Wang, 2007, Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells, Cancer Res., 67, 11830, 10.1158/0008-5472.CAN-07-1160 Wang, 2017, Bioproduction of Antibody-Drug Conjugate Payload Precursors by Engineered Cell Factories, Trends Biotechnol., 35, 466, 10.1016/j.tibtech.2017.03.001 Wargalla, 1989, Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells, Proc. Natl. Acad. Sci. U. S. A., 86, 5146, 10.1073/pnas.86.13.5146 Wayne, 2014, Immunotoxins for leukemia, Blood, 123, 2470, 10.1182/blood-2014-01-492256 Weber, 2003, Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma, J. Neuro-Oncol., 64, 125, 10.1007/BF02700027 Webster, 2012, Post-translational modification of plant-made foreign proteins; glycosylation and beyond, Biotechnol. Adv., 30, 410, 10.1016/j.biotechadv.2011.07.015 Wei, 2018, Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity, Proc. Natl. Acad. Sci. U. S. A., 115, E3501, 10.1073/pnas.1721780115 Wein, 2012, Small molecule inhibitors of Bacillus anthracis protective antigen proteolytic activation and oligomerization, J. Med. Chem., 55, 7998, 10.1021/jm300804e Weldon, 2011, A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer, FEBS J, 278, 4683, 10.1111/j.1742-4658.2011.08182.x Weldon, 2009, A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity, Blood, 113, 3792, 10.1182/blood-2008-08-173195 Wels, 1992, Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor, Cancer Res., 52, 6310 Whiteman, 2014, The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations, Blood, 124, 2321, 10.1182/blood.V124.21.2321.2321 Wichmann, 2017, The use of Quality-Adjusted Life Years in cost-effectiveness analyses in palliative care: Mapping the debate through an integrative review, Palliat. Med., 31, 306, 10.1177/0269216316689652 Wisløff, 2014, Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010, Pharmacoeconomics, 32, 367, 10.1007/s40273-014-0136-z Woitok, M., Klose, D., Di Fiore, S., Richter, W., Stein, C., Gresch, G., Grieger, E., Barth, S., Fischer, R., Kolberg, K. & Niesen, J., 2017. Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells. Onco Targets Ther., 10, 3313-3327. https://doi.org/10.2147/OTT.S140492. Woo, 2004, Increasing secretion of a bivalent anti-T-cell immunotoxin by Pichia pastoris, Appl. Environ. Microbiol., 70, 3370, 10.1128/AEM.70.6.3370-3376.2004 Wu, 1998, Sechiumin, a ribosome-inactivating protein from the edible gourd, Sechium edule Swartz--purification, characterization, molecular cloning and expression, Eur. J. Biochem., 255, 400, 10.1046/j.1432-1327.1998.2550400.x Xu, 2014, On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect, Pharm. Bioprocess., 2, 499, 10.4155/pbp.14.32 Yaghoubi, 2020, Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy, J. Cell. Physiol., 235, 31, 10.1002/jcp.28967 Yamauchi, 2014, Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells, Anticancer Res., 34, 5487 Yao, 2015, Plants as Factories for Human Pharmaceuticals: Applications and Challenges, Int. J. Mol. Sci., 16, 28549, 10.3390/ijms161226122 Yi, 2017, Brentuximab vedotin: clinical updates and practical guidance, Blood Res., 52, 243, 10.5045/br.2017.52.4.243 Yuan, 2011, Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency, BMC Cancer, 11, 61, 10.1186/1471-2407-11-61 Zauner, 2018, Structural analyses of Arabidopsis thaliana legumain gamma reveal differential recognition and processing of proteolysis and ligation substrates, J. Biol. Chem., 293, 8934, 10.1074/jbc.M117.817031 Zhang, 2006, Y55 and D78 are crucial amino acid residues of a new IgE epitope on trichosanthin, Biochem. Biophys. Res. Commun., 343, 1251, 10.1016/j.bbrc.2006.03.097 Zhang, C., Welborn, M., Zhu, T., Yang, N. J., Santos, M. S., Van Voorhis, T. & Pentelute, B. L., 2016. Pi-Clamp-mediated cysteine conjugation. Nat. Chem., 8, 120-8. https://doi.org/10.1038/nchem.2413. Zhao, 1999, Anti-HIV Agent Trichosanthin Enhances the Capabilities of Chemokines to Stimulate Chemotaxis and G Protein Activation, and This Is Mediated through Interaction of Trichosanthin and Chemokine Receptors, J Exp. Med., 190, 101, 10.1084/jem.190.1.101 Zhao, 2008, Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering, Protein Expr Purif, 61, 73, 10.1016/j.pep.2008.04.013 Zimmer, 2002, Cleavage at the Furin Consensus Sequence RAR/KR109 and Presence of the Intervening Peptide of the Respiratory Syncytial Virus Fusion Protein Are Dispensable for Virus Replication in Cell Culture, J. Virol., 76, 9218, 10.1128/JVI.76.18.9218-9224.2002 Zischewski, 2016, Overcoming low yields of plant-made antibodies by a protein engineering approach, Biotechnol. J., 11, 107, 10.1002/biot.201500255 Zuppone, 2019, Hosts for Hostile Protein Production: The Challenge of Recombinant Immunotoxin Expression, Biomedicines, 7, 38, 10.3390/biomedicines7020038